Login to Your Account

In The Clinic NEWS
LONDON – After surviving one phase III failure, the plug has finally been pulled on tecemotide when it became clear that the cancer vaccine was going to fail a phase II lung cancer study in Japan.
Shares of Receptos Inc. (NASDAQ:RCPT) spiked 20 percent last week, hitting a 52-week high of $61.13 on Thursday, after the abstract was posted for Saturday's late-breaker podium presentation at MS Boston 2014 of the complete dataset from the phase II portion of the company's phase II/III RADIANCE trial of RPC1063 in relapsing multiple sclerosis (RMS).
TAIPEI, Taiwan – Oncology-focused Aslan Pharmaceuticals Pte. Ltd. has started dosing the first patients in a safety study of its lead compound ASLAN001, a small-molecule, oral pan-HER inhibitor for the treatment of solid tumors.
More In The Clinic Headlines

Cast Your Vote

Has biotech’s bubble burst?: